CY1107649T1 - Συνδυασμος ο οποιος περιεχει ενα αντιφολικο αλας και παραγοντα ελαττωσης μεθυλομηλονικου οξεος - Google Patents

Συνδυασμος ο οποιος περιεχει ενα αντιφολικο αλας και παραγοντα ελαττωσης μεθυλομηλονικου οξεος

Info

Publication number
CY1107649T1
CY1107649T1 CY20071100756T CY071100756T CY1107649T1 CY 1107649 T1 CY1107649 T1 CY 1107649T1 CY 20071100756 T CY20071100756 T CY 20071100756T CY 071100756 T CY071100756 T CY 071100756T CY 1107649 T1 CY1107649 T1 CY 1107649T1
Authority
CY
Cyprus
Prior art keywords
methylphenolic
antifolic
salt
combination containing
acid reduction
Prior art date
Application number
CY20071100756T
Other languages
Greek (el)
English (en)
Inventor
Clet Niyikiza
Paolo Paoletti
James Jacob Rusthoven
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27396105&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1107649(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of CY1107649T1 publication Critical patent/CY1107649T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Detergent Compositions (AREA)
CY20071100756T 2000-06-30 2007-06-07 Συνδυασμος ο οποιος περιεχει ενα αντιφολικο αλας και παραγοντα ελαττωσης μεθυλομηλονικου οξεος CY1107649T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US21531000P 2000-06-30 2000-06-30
US23585900P 2000-09-27 2000-09-27
US28444801P 2001-04-18 2001-04-18
EP01948214A EP1313508B1 (en) 2000-06-30 2001-06-15 Combination containing an antifolate and methylmalonic acid lowering agent

Publications (1)

Publication Number Publication Date
CY1107649T1 true CY1107649T1 (el) 2013-04-18

Family

ID=27396105

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071100756T CY1107649T1 (el) 2000-06-30 2007-06-07 Συνδυασμος ο οποιος περιεχει ενα αντιφολικο αλας και παραγοντα ελαττωσης μεθυλομηλονικου οξεος

Country Status (11)

Country Link
US (4) US7053065B2 (enExample)
EP (1) EP1313508B1 (enExample)
JP (7) JP5102928B2 (enExample)
AT (1) ATE359823T1 (enExample)
AU (1) AU2001269688A1 (enExample)
CY (1) CY1107649T1 (enExample)
DE (1) DE60127970T2 (enExample)
DK (1) DK1313508T5 (enExample)
ES (1) ES2284660T3 (enExample)
PT (1) PT1313508E (enExample)
WO (1) WO2002002093A2 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60127970T2 (de) * 2000-06-30 2007-12-20 Eli Lilly And Co., Indianapolis Zusammensetzung, welche ein antifolate und ein methylmalonsäuresenkendes mittel enthält
PL1874821T3 (pl) 2005-04-26 2013-09-30 Trion Pharma Gmbh Kombinacja przeciwciał i glikokortykoidów do leczenia raka
AU2007204410A1 (en) * 2006-01-12 2007-07-19 Novartis Ag Combination of mTOR inhibitor and antipolate compound
WO2010021843A1 (en) * 2008-08-20 2010-02-25 Eli Lilly And Company Use of antifolates in patients with detectable levels of tff-1 for the cancer treatment
WO2010138955A2 (en) 2009-05-29 2010-12-02 University Of Florida Research Foundation, Inc. Methods and compositions for treating neoplasia
JP5899241B2 (ja) 2010-12-21 2016-04-06 ネクター セラピューティクス ペメトレキセドベースの化合物のマルチアームポリマープロドラッグコンジュゲート
SI2854768T1 (sl) 2012-05-30 2017-08-31 Fresenius Kabi Oncology Limited Farmacevtski sestavki pemetrekseda
SG11201609981RA (en) 2014-06-04 2016-12-29 Thomas Helledays Stiftelse För Medicinsk Forskning Mth1 inhibitors for treatment of inflammatory and autoimmune conditions
EP3297694A1 (en) 2015-05-21 2018-03-28 Musculoskeletal Transplant Foundation Modified demineralized cortical bone fibers
CA2994167A1 (en) * 2015-07-30 2017-02-02 Expression Pathology, Inc. Quantifying fr-a and gart proteins for optimal cancer therapy
HUE069668T2 (hu) * 2015-12-07 2025-04-28 General Oncology Inc Kombináció a metasztatikus rák hatékony kezelésére betegeknél
EP3496757A4 (en) 2016-08-12 2020-04-15 L.E.A.F Holdings Group LLC POLYGLUTAMATE ANTIFOLATES AND USES THEREOF.
US20180236098A1 (en) 2016-08-12 2018-08-23 L.E.A.F. Holdings Group Llc Alpha and gamma-d polyglutamated antifolates and uses thereof
US11584733B2 (en) 2017-01-09 2023-02-21 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
US11034667B2 (en) 2017-01-09 2021-06-15 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
CN112004537A (zh) 2018-01-09 2020-11-27 穿梭药业公司 用于治疗人疾病的选择性组蛋白去乙酰化酶抑制剂
CA3090506A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Alpha polyglutamated tetrahydrofolates and uses thereof
EP3749318A4 (en) 2018-02-07 2022-07-06 L.E.A.F Holdings Group LLC GAMMA-POLYGLUTAMATED RALTITREXED AND ITS USES
US12076402B2 (en) 2018-02-07 2024-09-03 L.E.A.F. Holdings Group Llc Alpha polyglutamated antifolates and uses thereof
US12246015B2 (en) 2018-02-07 2025-03-11 L.E.A.F. Holdings Group Llc Alpha polyglutamated raltitrexed and uses thereof
WO2019157145A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Gamma polyglutamated pemetrexed and uses thereof
US12246019B2 (en) 2018-02-07 2025-03-11 L.E.A.F. Holdings Group Llc Alpha polyglutamated lometrexol and uses thereof
JP7491573B2 (ja) 2018-02-07 2024-05-28 エル．イー．エー．エフ． ホールディングス グループ エルエルシー アルファポリグルタミン酸化メトトレキセートおよびその使用
US12220431B2 (en) 2018-02-07 2025-02-11 L.E.A.F. Holdings Group Llc Gamma polyglutamated antifolates and uses thereof
EP3749317A4 (en) 2018-02-07 2022-06-22 L.E.A.F Holdings Group LLC PEMETREXED ALPHA-POLYGLUTAMATE AND ASSOCIATED USES
US11730738B2 (en) 2018-02-07 2023-08-22 L.E.A.F. Holdings Group Llc Alpha polyglutamated pralatrexate and uses thereof
US12310966B2 (en) 2018-02-07 2025-05-27 L.E.A.F. Holdings Group Llc Alpha polyglutamated aminopterin and uses thereof
WO2019160734A1 (en) 2018-02-14 2019-08-22 L.E.A.F. Holdings Group Llc Gamma polyglutamated lometrexol and uses thereof
EP3752158A4 (en) 2018-02-14 2022-03-09 L.E.A.F Holdings Group LLC GAMMA-POLYGLUTAMATED AMINOPTERINE AND USES THEREOF
WO2019160735A1 (en) 2018-02-14 2019-08-22 L.E.A.F. Holdings Group Llc Gamma polyglutamated tetrahydrofolates and uses thereof
CA3090753A1 (en) 2018-02-14 2019-08-22 L.E.A.F. Holdings Group Llc Gamma polyglutamated pralatrexate and uses thereof
CA3090989A1 (en) 2018-02-14 2019-08-22 L.E.A.F. Holdings Group Llc Gamma polyglutamated methotrexate and uses thereof
WO2023177894A1 (en) 2022-03-18 2023-09-21 Ideaya Biosciences, Inc. Combination therapy comprising a mat2a inhibitor and an antimetabolite agent
WO2025247952A1 (en) * 2024-05-30 2025-12-04 Université De Fribourg Inhibition of cyanide overproduction for the therapy of down syndrome and nonketotic hyperglycinemia

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US225030A (en) * 1880-03-02 Rotary engine
US216350A (en) * 1879-06-10 Improvement in car-replacers
US2920015A (en) * 1957-08-27 1960-01-05 Armour & Co Long-acting vitamin b12
CH588505A5 (enExample) * 1972-06-08 1977-06-15 Research Corp
US5563126A (en) 1986-11-20 1996-10-08 Metabolite Laboratories Method for treatment and prevention of deficiencies of vitamins B12, folic acid, and B6
JP2962755B2 (ja) * 1989-02-28 1999-10-12 帝人株式会社 新規ビタミンｂ▲下１▼▲下２▼誘導体、その製造方法並びにその用途
US5405839A (en) 1989-02-28 1995-04-11 Teijin Limited Vitamin B12 derivative, preparation process thereof, and use thereof
KR0162654B1 (ko) * 1989-12-11 1998-11-16 알렌 제이. 시니스갤리 N-(피롤로[2,3-d]피리미딘-3-일아크릴)-글루타민산 유도체
ATE126700T1 (de) * 1991-03-29 1995-09-15 Lilly Co Eli Verbesserte therapiemethode.
JPH05163160A (ja) * 1991-12-13 1993-06-29 Snow Brand Milk Prod Co Ltd 免疫低下に伴う感染症の予防及び治療用栄養剤
US6207651B1 (en) 1996-08-02 2001-03-27 Metabolite Laboratories Method for treatment and prevention of deficiencies of vitamins B12, folic acid, and B6
WO1995027723A1 (en) 1994-04-08 1995-10-19 Receptagen Corporation Receptor modulating agents and methods relating thereto
AU3972195A (en) 1994-10-12 1996-05-06 Research & Diagnostics Systems, Inc. Reticulocyte assay control
DE60127970T2 (de) * 2000-06-30 2007-12-20 Eli Lilly And Co., Indianapolis Zusammensetzung, welche ein antifolate und ein methylmalonsäuresenkendes mittel enthält
US20040005311A1 (en) * 2001-07-20 2004-01-08 Pitman Bradford D. Dietary supplement compositions

Also Published As

Publication number Publication date
JP2015178501A (ja) 2015-10-08
DE60127970D1 (de) 2007-05-31
US7772209B2 (en) 2010-08-10
US7053065B2 (en) 2006-05-30
JP5469706B2 (ja) 2014-04-16
JP2020117536A (ja) 2020-08-06
ATE359823T1 (de) 2007-05-15
ES2284660T3 (es) 2007-11-16
JP2017019852A (ja) 2017-01-26
JP5102928B2 (ja) 2012-12-19
JP2012180381A (ja) 2012-09-20
US20080032948A1 (en) 2008-02-07
DE60127970T2 (de) 2007-12-20
WO2002002093A3 (en) 2003-02-06
US20060079480A1 (en) 2006-04-13
US20100210583A1 (en) 2010-08-19
US20030212038A1 (en) 2003-11-13
AU2001269688A1 (en) 2002-01-14
EP1313508B1 (en) 2007-04-18
PT1313508E (pt) 2007-06-21
EP1313508A2 (en) 2003-05-28
WO2002002093A2 (en) 2002-01-10
DK1313508T3 (da) 2007-08-06
DK1313508T5 (da) 2017-03-20
JP2014005304A (ja) 2014-01-16
JP2004501964A (ja) 2004-01-22
JP2018197265A (ja) 2018-12-13

Similar Documents

Publication Publication Date Title
CY1107649T1 (el) Συνδυασμος ο οποιος περιεχει ενα αντιφολικο αλας και παραγοντα ελαττωσης μεθυλομηλονικου οξεος
NO20054988D0 (no) Preparater og metoder for behandling av cancer
PT1410791E (pt) Forma galénica apta a ser administrada oralmente compreendendo metformina e um agente promotor da absorção
SE0301886D0 (sv) New use V
DK1603565T3 (da) Medikament omfattende en höjaktiv længevarende beta2-agonisk i kombination med andre aktive ingredienser
NO20024309D0 (no) Intradermal penetreringsmidler for topikal lokal anestetisk administrering
BRPI0317696B8 (pt) composição para branqueamento
ATE489101T1 (de) Wiederherstellung der gelenken mit mesenchymalen stammzellen
BR0113925A (pt) Derivados de ácido 2-amino-2-alquil-5 heptenóico e heptinóico úteis como inibidores da sintase de óxido nìtrico
DE602004001692D1 (de) "No-mix" multiminerale Haarentkräuselungsmitteln
DK1301201T3 (da) Behandling af glycogenosis type II
MXPA03005505A (es) Compuesto modafinilo y mezclas de ciclodextrina.
EE200300103A (et) Kontratseptsioonimeetod ja kontratseptiivi manustatav vorm
EA200200492A1 (ru) Растворы, содержащие эпинастин
EA200870091A1 (ru) Применение бензоконденсированных гетероциклических сульфамидных производных для снятия боли
FI20001715L (fi) Rankoihin liittyvõt jõrjestelyt ja menetelmõt
MY122838A (en) Treating allergic and inflammatory conditions
DK1621207T3 (da) Mixture of defibrotide and G-CSF, and its use for activating haematopoietic progenitors
DE50110248D1 (de) Federstahl vom maraging-typ
DE50111407D1 (de) Mittel enthaltend n-chlortaurin sowie dessen verwendung zur behandlung von schleimhautpolypen
SE0301883D0 (sv) New use II
DE60124516D1 (de) Kombination des lezithins mit ascorbinsäure
SI1333819T1 (sl) Inhalacijska formulacija v raztopini s tiotropijevo soljo
SE0301884D0 (sv) New use III
SE0301885D0 (sv) New use IV